Cargando…
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
Previously, indirect thrombin inhibitors such as unfractionated heparin or low-molecular-weight heparin were used as a standard anticoagulation during percutaneous coronary intervention to prevent procedural thrombotic complications but at a risk of hemorrhagic complications. More recently, bivaliru...
Autores principales: | Ramana, Ravi K, Lewis, Bruce E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515410/ https://www.ncbi.nlm.nih.gov/pubmed/18827868 |
Ejemplares similares
-
Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006) -
Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015) -
Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019) -
The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017) -
The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014)